{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:52:00Z","timestamp":1785369120315,"version":"3.55.0"},"posted":{"date-parts":[[2025,12,3]]},"group-title":"Health Systems and Quality Improvement","reference-count":95,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Slow-release oral morphine (SROM) was introduced as an alternative form of opioid agonist treatment (OAT) in British Columbia (BC), Canada in 2017. While clinical guidelines in BC recommend SROM based on expert consensus and experience, there is limited real-world evidence on populations most likely to benefit from SROM compared to other forms of OAT, particularly in the context of widespread fentanyl exposure. We will estimate the comparative effectiveness of SROM versus methadone and buprenorphine\/naloxone on OAT discontinuation and all-cause mortality among key sub-populations in BC.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We will conduct a population-level retrospective cohort study using linked data from nine provincial health administrative databases. The study population includes adults (\u226518 years) in BC who initiated SROM, methadone, or buprenorphine\/naloxone between June 1, 2017, and December 31, 2022. Key sub-populations will include incident users with no prior OAT history and prevalent new users with prior OAT experience stratified by OAT type, stability, and medication switching history. The primary outcomes are time to OAT discontinuation and all-cause mortality, while overdose-related acute care visits will be examined as a secondary outcome. To estimate both the initiator effect and the effect of treatment at guideline-recommended doses, we will apply marginal structural models using inverse probability treatment weighting and \u2018clone-censor-weights\u2019 approach to address confounding by indication and time-varying confounding. Sensitivity analyses will evaluate the robustness of our findings, including cohort and timeline restrictions, alternative outcome definitions, and alternative estimation strategies including high-dimensional propensity score and instrumental variable approaches.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>This study will generate real-world evidence on the comparative effectiveness of SROM versus methadone and buprenorphine\/naloxone across clinically distinct OAT sub-populations. The findings will support evidence-informed updates to OAT guidelines and clinical decision-making in BC and other jurisdictions facing escalating opioid-related harms.<\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2025.11.30.25341316","type":"posted-content","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:06:16Z","timestamp":1765278376000},"source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness of slow-release oral morphine versus other OAT regimens in key sub-populations: protocol for population-based target trial emulation"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2624-2118","authenticated-orcid":false,"given":"Momenul Haque","family":"Mondol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Eun","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Zanette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Eugenia","family":"Soc\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Gustafson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2413-9133","authenticated-orcid":false,"given":"Paxton","family":"Bach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert William","family":"Platt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Seaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander","family":"Greenland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohdan","family":"Nosyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2025120902594538000_2025.11.30.25341316v1.1","unstructured":"Ministry of Health. New Zealand practice guidelines for opioid substitution treatment. 2014."},{"key":"2025120902594538000_2025.11.30.25341316v1.2","unstructured":"Clinical Guidelines on Drug Misuse and Dependence Update 2017 Independent Expert Working Group (2017). Drug misuse and dependence: UK guidelines on clinical management. London: Department of Health."},{"key":"2025120902594538000_2025.11.30.25341316v1.3","unstructured":"Gowing L Ardafmln . National Guidelines for Medication-Assisted Treatment of Opioid Dependence. Commonwealth of Australia; 2014."},{"key":"2025120902594538000_2025.11.30.25341316v1.4","unstructured":"New South Wales Ministry of H. NSW Clinical Guidelines: Treatment of Opioid Dependence - 2018. NSW Ministry of Health; 2018."},{"key":"2025120902594538000_2025.11.30.25341316v1.5","unstructured":"Canadian Research Initiative in Substance Misuse. CRISM national guideline for the clinical management of opioid use disorder. Canadian Institutes on Health Research; 2018."},{"key":"2025120902594538000_2025.11.30.25341316v1.6","unstructured":"British Columbia Centre on Substance Use (BCCSU). A guideline for the clinical management of opioid use disorder. 2023. https:\/\/www.bccsu.ca\/wp-content\/uploads\/2023\/12\/BC-OUD-Treatment-Guideline_2023-Update.pdf."},{"key":"2025120902594538000_2025.11.30.25341316v1.7","unstructured":"Clinical Guidelines on Drug Misuse and Dependence, Update 2017 Independent Expert Working Group. Drug misuse and dependence: UK guidelines on clinical management. Global and Public Health\/ Population Health\/ Healthy Behaviours, 2017."},{"key":"2025120902594538000_2025.11.30.25341316v1.8","unstructured":"British Columbia Centre on Substance Use (BCCSU). A guideline for the clinical management of opioid use disorder. 2017. http:\/\/www.bccsu.ca\/wp-content\/uploads\/2017\/06\/BC-OUD-Guidelines_June2017.pdf."},{"key":"2025120902594538000_2025.11.30.25341316v1.9","unstructured":"Centre for Addiction and Mental Health. Opioid Agonist Therapy: A Synthesis of Canadian Guidelines for Treating Opioid Use Disorder. [Internet]. 2021 May [cited 2023 Dec 20]. Available from: www.camh.ca"},{"key":"2025120902594538000_2025.11.30.25341316v1.10","unstructured":"Queensland Opioid Dependence Treatment Guidelines 2023. Publisher: The State of Queensland (Queensland Health). Available: https:\/\/www.health.qld.gov.au\/data\/assets\/pdf_file\/0024\/1246605\/Queensland-Opioid-Dependence-Treatment-Guidelines-2023.pdf."},{"key":"2025120902594538000_2025.11.30.25341316v1.11","unstructured":"Cheema K , Kahan M , Rodgers J , Smoke A , Turner S , Wyman J , et al. Recommendations for use of slow-release oral morphine as opioid agonist therapy. In: META:PHI, editor. Toronto, ON:2023."},{"issue":"9535","key":"2025120902594538000_2025.11.30.25341316v1.12","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0140-6736(06)69173-3","article-title":"QTc prolongation: methadone\u2019s efficacy-safety paradox","volume":"368","year":"2006","journal-title":"The Lancet"},{"issue":"2","key":"2025120902594538000_2025.11.30.25341316v1.13","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4103\/jpp.JPP_163_17","article-title":"Comprehensive Review on Methadone-Induced QT Prolongation and Torsades","volume":"9","year":"2018","journal-title":"J Pharmacol Pharmacother"},{"key":"2025120902594538000_2025.11.30.25341316v1.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2014.05.012"},{"issue":"2","key":"2025120902594538000_2025.11.30.25341316v1.15","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10840-021-01072-1","article-title":"Effects of opioid receptor agonist and antagonist medications on electrocardiogram changes and presentation of cardiac arrhythmia: review article","volume":"63","year":"2022","journal-title":"Journal of Interventional Cardiac Electrophysiology"},{"key":"2025120902594538000_2025.11.30.25341316v1.16","unstructured":"The national overall count from January 2016 to June 2023 includes deaths from British Columbia (2019 to 2023 [Jan to Jun]) related to all illicit drugs and Quebec (2021 to 2023 [Jan to Jun]) related to drug or opioid-related intoxication."},{"issue":"9","key":"2025120902594538000_2025.11.30.25341316v1.17","doi-asserted-by":"crossref","first-page":"e2334540","DOI":"10.1001\/jamanetworkopen.2023.34540","article-title":"Buprenorphine Dose and Time to Discontinuation Among Patients With Opioid Use Disorder in the Era of Fentanyl","volume":"6","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2025120902594538000_2025.11.30.25341316v1.18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.03923.x"},{"key":"2025120902594538000_2025.11.30.25341316v1.19","doi-asserted-by":"crossref","unstructured":"Ferri M , Minozzi S , Bo A , Amato L . Slow-release oral morphine as maintenance therapy for opioid dependence. Cochrane Database of Systematic Reviews. 2013 Jun 5;","DOI":"10.1002\/14651858.CD009879.pub2"},{"key":"2025120902594538000_2025.11.30.25341316v1.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2005.001128.x"},{"issue":"2","key":"2025120902594538000_2025.11.30.25341316v1.21","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/JCP.0000000000000288","article-title":"Self-Reported Cravings for Heroin and Cocaine During Maintenance Treatment With Slow-Release Oral Morphine Compared With Methadone","volume":"35","year":"2015","journal-title":"J Clin Psychopharmacol"},{"key":"2025120902594538000_2025.11.30.25341316v1.22","unstructured":"Cheema K , Kahan M , Rodgers J , Smoke A , Turner S , Wyman J , Zhang M. Recommendations for use of slow-release oral morphine as opioid agonist therapy. Toronto, ON: META:PHI; 2023. www.metaphi.ca."},{"key":"2025120902594538000_2025.11.30.25341316v1.23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-025799"},{"key":"2025120902594538000_2025.11.30.25341316v1.24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0266142"},{"key":"2025120902594538000_2025.11.30.25341316v1.25","doi-asserted-by":"publisher","DOI":"10.1080\/10826080500391845"},{"key":"2025120902594538000_2025.11.30.25341316v1.26","doi-asserted-by":"crossref","first-page":"105993","DOI":"10.1016\/j.cct.2020.105993","article-title":"Slow release oral morphine versus methadone for opioid use disorder in the fentanyl era (pRESTO): Protocol for a non-inferiority randomized clinical trial","volume":"91","year":"2020","journal-title":"Contemp Clin Trials"},{"key":"2025120902594538000_2025.11.30.25341316v1.27","doi-asserted-by":"crossref","unstructured":"Anand R , Penta S , Cui Z , Fairbairn N , Socias ME . Redesigning a Stopped Clinical Trial as an Emulated Trial Using Real-World Data to Explore the Effectiveness of Slow-Release Oral Morphine as a Treatment for Opioid Use Disorder. Substance use & addiction journal. 2024 Oct 11;29767342241279170.","DOI":"10.1177\/29767342241279167"},{"issue":"1","key":"2025120902594538000_2025.11.30.25341316v1.28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jphs.2020.06.004","article-title":"Switching opioid-dependent patients in substitution treatment from racemic methadone, levomethadone and buprenorphine to slow-release oral morphine: Analysis of the switching process in routine care","volume":"144","year":"2020","journal-title":"J Pharmacol Sci"},{"key":"2025120902594538000_2025.11.30.25341316v1.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108350"},{"issue":"2","key":"2025120902594538000_2025.11.30.25341316v1.30","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/dar.13365","article-title":"Uptake of slow-release oral morphine as opioid agonist treatment among hospitalised patients with opioid use disorder","volume":"41","year":"2022","journal-title":"Drug Alcohol Rev"},{"issue":"5","key":"2025120902594538000_2025.11.30.25341316v1.31","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/fcp.12210","article-title":"Evidence of slow-release morphine sulfate abuse and diversion: epidemiological approaches in a French administrative area","volume":"30","year":"2016","journal-title":"Fundam Clin Pharmacol"},{"key":"2025120902594538000_2025.11.30.25341316v1.32","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14082"},{"issue":"1","key":"2025120902594538000_2025.11.30.25341316v1.33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12954-021-00473-9","article-title":"Retention in the Austrian opioid agonist treatment system: a national prospective cohort study","volume":"18","year":"2021","journal-title":"Harm Reduct J"},{"key":"2025120902594538000_2025.11.30.25341316v1.34","unstructured":"Lam V , Sankey C , Wyman J , et al. COVID-19 Opioid Agonist Treatment Guidance: META:PHI, Centre for Addiction and Mental Health and Ontario Medical Association (OMA); 2021. Available from: https:\/\/www.camh.ca\/-\/media\/health-info-files\/covid-19-2023\/covid-19-modifications-to-opioid-agonist-treatment-delivery-pdf.pdf."},{"key":"2025120902594538000_2025.11.30.25341316v1.35","doi-asserted-by":"crossref","first-page":"103573","DOI":"10.1016\/j.drugpo.2021.103573","article-title":"Evaluating how has care been affected by the Ontario COVID-19 Opioid Agonist Treatment Guidance: Patients\u2019 and prescribers\u2019 experiences with changes in unsupervised dosing","volume":"102","year":"2022","journal-title":"International Journal of Drug Policy"},{"issue":"3","key":"2025120902594538000_2025.11.30.25341316v1.36","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1016\/S2468-2667(23)00023-3","article-title":"Synthesising evidence of the effects of COVID-19 regulatory changes on methadone treatment for opioid use disorder: implications for policy","volume":"8","year":"2023","journal-title":"Lancet Public Health"},{"key":"2025120902594538000_2025.11.30.25341316v1.37","doi-asserted-by":"crossref","first-page":"104302","DOI":"10.1016\/j.drugpo.2023.104302","article-title":"Adoption of methadone take home policy by U.S. state opioid treatment authorities during COVID-19","volume":"124","year":"2024","journal-title":"International Journal of Drug Policy"},{"issue":"5","key":"2025120902594538000_2025.11.30.25341316v1.38","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/dar.13382","article-title":"Opioid agonist treatment and patient outcomes during the COVID-19 pandemic in south east Sydney, Australia","volume":"41","year":"2022","journal-title":"Drug Alcohol Rev"},{"key":"2025120902594538000_2025.11.30.25341316v1.39","unstructured":"Crawshaw J. Addendum to the New Zealand Practice Guidelines for Opioid Substitution Treatment 2014 Wellington, New Zealand: Ministry of Health; 2014. Available from: https:\/\/www.tewhatuora.govt.nz\/assets\/For-the-health-sector\/COVID-19-Information\/COVID-19-\/addendum_to_the_new_zealand_practice_guidelines_for_opioid_substitution_treatment_2014.pdf."},{"issue":"S2","key":"2025120902594538000_2025.11.30.25341316v1.40","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.2105\/AJPH.2021.306654","article-title":"Structural Adaptations to Methadone Maintenance Treatment and Take-Home Dosing for Opioid Use Disorder in the Era of COVID-19","volume":"112","year":"2022","journal-title":"Am J Public Health"},{"key":"2025120902594538000_2025.11.30.25341316v1.41","doi-asserted-by":"crossref","first-page":"109049","DOI":"10.1016\/j.drugalcdep.2021.109049","article-title":"The impact of COVID-19 on opioid treatment programs in the United States","volume":"228","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"2025120902594538000_2025.11.30.25341316v1.42","doi-asserted-by":"publisher","DOI":"10.1111\/add.13789"},{"key":"2025120902594538000_2025.11.30.25341316v1.43","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.21383"},{"key":"2025120902594538000_2025.11.30.25341316v1.44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2113319"},{"key":"2025120902594538000_2025.11.30.25341316v1.45","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwv254"},{"key":"2025120902594538000_2025.11.30.25341316v1.46","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e3182114039"},{"key":"2025120902594538000_2025.11.30.25341316v1.47","unstructured":"BC Ministry of Health [creator] (2018). PharmaNet. British Columbia Ministry of Health [publisher]. Data Extract. MOH (2018). http:\/\/www.health.gov.bc.ca\/data\/."},{"key":"2025120902594538000_2025.11.30.25341316v1.48","unstructured":"BC Ministry of Health [creator] (2018). Discharge Abstract Database (Hospital Separations). British Columbia Ministry of Health [publisher]. Data Extract. MOH (2018). http:\/\/www.health.gov.bc.ca\/data\/."},{"key":"2025120902594538000_2025.11.30.25341316v1.49","unstructured":"BC Ministry of Health [creator] (2018). Medical Services Plan (MSP) Payment Information File. British Columbia Ministry of Health [publisher]. Data Extract. MOH (2018). http:\/\/www.health.gov.bc.ca\/data\/."},{"key":"2025120902594538000_2025.11.30.25341316v1.50","unstructured":"BC Vital Statistics Agency [creator] (2018). Vital Statistics Deaths. British Columbia Ministry of Health [publisher]. Data Extract. MOH (2018). http:\/\/www.health.gov.bc.ca\/data\/."},{"key":"2025120902594538000_2025.11.30.25341316v1.51","unstructured":"Ministry of Public Safety and Solicitor General (PSSG) [creator] (2018). BC Corrections Dataset. British Columbia Ministry of Health [publisher]. Data Extract. MOH (2018). http:\/\/www.health.gov.bc.ca\/data\/."},{"key":"2025120902594538000_2025.11.30.25341316v1.52","unstructured":"Perinatal Services BC [creator] (2018). British Columbia Perinatal Data Registry. British Columbia Ministry of Health [publisher]. Data Extract. MOH (2018). http:\/\/www.health.gov.bc.ca\/data\/."},{"key":"2025120902594538000_2025.11.30.25341316v1.53","unstructured":"BC Ministry of Health [creator] (2018). National Ambulatory Care Reporting System (NACRS). British Columbia Ministry of Health [publisher]. Data Extract. MOH (2018). http:\/\/www.health.gov.bc.ca\/data\/."},{"key":"2025120902594538000_2025.11.30.25341316v1.54","unstructured":"British Columbia Ministry of Health [creator] (2022). Data from: Client Roster. British Columbia Ministry of Health [publisher]. Data Extract. MOH (2022). http:\/\/www.health.gov.bc.ca\/data\/."},{"key":"2025120902594538000_2025.11.30.25341316v1.55","unstructured":"British Columbia Ministry of Social Development and Poverty Reduction [creator] (2020). Social Development and Poverty Reduction Database (SDPR). British Columbia Ministry of Health [publisher]. Data Extract. MOH (2020). http:\/\/www.health.gov.bc.ca\/data\/."},{"key":"2025120902594538000_2025.11.30.25341316v1.56","unstructured":"Government of British Columbia. Personal Health Identification [Available from: https:\/\/www2.gov.bc.ca\/gov\/content\/health\/health-drug-coverage\/msp\/bc-residents\/personal-health-identification."},{"issue":"5","key":"2025120902594538000_2025.11.30.25341316v1.57","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/add.15737","article-title":"Opioid agonist treatment uptake within provincial correctional facilities in British Columbia, Canada","volume":"117","year":"2022","journal-title":"Addiction"},{"issue":"21","key":"2025120902594538000_2025.11.30.25341316v1.58","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1001\/jama.2024.16954","article-title":"Buprenorphine\/Naloxone vs Methadone for the Treatment of Opioid Use Disorder","volume":"332","year":"2024","journal-title":"JAMA"},{"issue":"5","key":"2025120902594538000_2025.11.30.25341316v1.59","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1093\/ije\/dyaa057","article-title":"Reflection on modern methods: trial emulation in the presence of immortal-time bias. Assessing the benefit of major surgery for elderly lung cancer patients using observational data","volume":"49","year":"2020","journal-title":"Int J Epidemiol"},{"key":"2025120902594538000_2025.11.30.25341316v1.60","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyaa223"},{"key":"2025120902594538000_2025.11.30.25341316v1.61","doi-asserted-by":"publisher","DOI":"10.1177\/1060028016648367"},{"key":"2025120902594538000_2025.11.30.25341316v1.62","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-019-00494-6"},{"key":"2025120902594538000_2025.11.30.25341316v1.63","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-036102"},{"key":"2025120902594538000_2025.11.30.25341316v1.64","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-068729"},{"key":"2025120902594538000_2025.11.30.25341316v1.65","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwn164"},{"key":"2025120902594538000_2025.11.30.25341316v1.66","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-200009000-00011"},{"key":"2025120902594538000_2025.11.30.25341316v1.67","doi-asserted-by":"crossref","first-page":"107127","DOI":"10.1016\/j.ypmed.2022.107127","article-title":"To curb research misreporting, replace significance and confidence by compatibility: A Preventive Medicine Golden Jubilee article","volume":"164","year":"2022","journal-title":"Prev Med (Baltim"},{"key":"2025120902594538000_2025.11.30.25341316v1.68","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e3181df1b69"},{"key":"2025120902594538000_2025.11.30.25341316v1.69","doi-asserted-by":"crossref","unstructured":"Limozin JM , Seaman SR , Su L . Inference procedures in sequential trial emulation with survival outcomes: Comparing confidence intervals based on the sandwich variance estimator, bootstrap and jackknife. Stat Methods Med Res. 2025 Jul 9;","DOI":"10.1177\/09622802251356594"},{"key":"2025120902594538000_2025.11.30.25341316v1.70","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0000000000000581"},{"key":"2025120902594538000_2025.11.30.25341316v1.71","doi-asserted-by":"publisher","DOI":"10.1097\/01.ede.0000222409.00878.37"},{"key":"2025120902594538000_2025.11.30.25341316v1.72","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3"},{"issue":"2","key":"2025120902594538000_2025.11.30.25341316v1.73","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/EDE.0000000000000787","article-title":"Can We Train Machine Learning Methods to Outperform the High-dimensional Propensity Score Algorithm?","volume":"29","year":"2018","journal-title":"Epidemiology"},{"issue":"2","key":"2025120902594538000_2025.11.30.25341316v1.74","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/EDE.0000000000001697","article-title":"Comparative Analysis of Instrumental Variables on the Assignment of Buprenorphine\/Naloxone or Methadone for the Treatment of Opioid Use Disorder","volume":"35","year":"2024","journal-title":"Epidemiology"},{"key":"2025120902594538000_2025.11.30.25341316v1.75","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0000000000000287"},{"issue":"3","key":"2025120902594538000_2025.11.30.25341316v1.76","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/rssb.12262","article-title":"Bounded, Efficient and Multiply Robust Estimation of Average Treatment Effects Using Instrumental Variables","volume":"80","year":"2018","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"2025120902594538000_2025.11.30.25341316v1.77","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0000000000000279"},{"key":"2025120902594538000_2025.11.30.25341316v1.78","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhealeco.2007.09.009"},{"issue":"2","key":"2025120902594538000_2025.11.30.25341316v1.79","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/biom.13792","article-title":"Instrumental Variable Estimation of the Causal Hazard Ratio","volume":"79","year":"2023","journal-title":"Biometrics"},{"issue":"1","key":"2025120902594538000_2025.11.30.25341316v1.80","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/1740774511420743","article-title":"Beyond the intention-to-treat in comparative effectiveness research","volume":"9","year":"2012","journal-title":"Clinical Trials"},{"key":"2025120902594538000_2025.11.30.25341316v1.81","unstructured":"Canadian Institutes of Health Research NS and ERC of C and SS and HRC. Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans. Canada; 2018 Dec."},{"key":"2025120902594538000_2025.11.30.25341316v1.82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"2025120902594538000_2025.11.30.25341316v1.83","unstructured":"World Health O. World Health Organization Model List of Essential Medicines - 22nd list, 2021. World Health Organization; 2021."},{"key":"2025120902594538000_2025.11.30.25341316v1.84","doi-asserted-by":"crossref","unstructured":"Sordo L , Barrio G , Bravo MJ , Indave BI , Degenhardt L , Wiessing L , et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017 Apr 26;j1550.","DOI":"10.1136\/bmj.j1550"},{"key":"2025120902594538000_2025.11.30.25341316v1.85","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.drugpo.2018.06.003","article-title":"Developing a patient-reported experience questionnaire with and for people who use drugs: A community engagement process in Vancouver\u2019s Downtown Eastside","volume":"59","year":"2018","journal-title":"International Journal of Drug Policy"},{"key":"2025120902594538000_2025.11.30.25341316v1.86","unstructured":"BC Ministry of Health. B.C. Health System Strategy: Geographic Service Areas. 2016."},{"key":"2025120902594538000_2025.11.30.25341316v1.87","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"issue":"12","key":"2025120902594538000_2025.11.30.25341316v1.88","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1111\/add.15515","article-title":"Opioid analgesic prescribing for opioid-na\u00efve individuals prior to identification of opioid use disorder in British Columbia, Canada","volume":"116","year":"2021","journal-title":"Addiction"},{"key":"2025120902594538000_2025.11.30.25341316v1.89","unstructured":"British Columbia Centre on Substance Use. COVID-19: Information for Opioid Agonist Treatment Prescribers and Pharmacists 2020 [Available from: https:\/\/www.bccsu.ca\/wp-content\/uploads\/2020\/05\/COVID-19-Bulletin-May-20-2020.pdf accessed Sep. 17 2024."},{"key":"2025120902594538000_2025.11.30.25341316v1.90","unstructured":"Oetter HM . COVID-19: Important update from the registrar: College of Physicians and Surgeons of British Columbia; 2020 [Available from: https:\/\/www.cpsbc.ca\/files\/pdf\/2020-03-24-COVID-19-Update-from-the-Registrar.pdf accessed Sep. 17 2024."},{"key":"2025120902594538000_2025.11.30.25341316v1.91","unstructured":"College of Pharmacists of British Columbia. Changes to the Delivery Requirements for OAT Now In Effect 2020 [Available from: https:\/\/www.bcpharmacists.org\/news\/changes-delivery-requirements-oat-now-effect accessed Sep. 17 2024."},{"key":"2025120902594538000_2025.11.30.25341316v1.92","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000166"},{"issue":"6","key":"2025120902594538000_2025.11.30.25341316v1.93","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/ADM.0000000000000156","article-title":"Evaluating the Effectiveness of First-Time Methadone Maintenance Therapy Across Northern, Rural, and Urban Regions of Ontario, Canada","volume":"9","year":"2015","journal-title":"J Addict Med"},{"key":"2025120902594538000_2025.11.30.25341316v1.94","unstructured":"Federal, provincial, and territorial Special Advisory Committee on the Epidemic of Opioid Overdoses. Opioid- and Stimulant-related Harms in Canada. Ottawa: Public Health Agency of Canada [Internet]. 2023 [cited 2024 Mar 24]. Available from: https:\/\/health-infobase.canada.ca\/substance-related-harms\/opioids-stimulants\/"},{"key":"2025120902594538000_2025.11.30.25341316v1.95","unstructured":"Characteristics of patients with repeat emergency department visits for opioid-related harms in Alberta, Ontario and the Yukon [Internet]. [cited 2024 Aug 2]. Available from: https:\/\/www.canada.ca\/en\/health-canada\/services\/opioids\/data-surveillance-research.html"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2025.11.30.25341316","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:06:43Z","timestamp":1765278403000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.64898\/2025.11.30.25341316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":95,"URL":"https:\/\/doi.org\/10.64898\/2025.11.30.25341316","relation":{},"subject":[],"published":{"date-parts":[[2025,12,3]]},"subtype":"preprint"}}